CA-A Cancer Journal for Clinicians

CA: A Cancer Journal for Clinicians is the flagship peer-reviewed oncology journal of the American Cancer Society, published by Wiley, founded in 1950, covering cancer prevention, early detection, treatment and survivorship, with a 2025 Journal Impact Factor of 685.2（CA: A Cancer Journal for Clinicians）是美国癌症学会的旗舰同行评审肿瘤学期刊，由 Wiley 出版，1950 年创刊，聚焦癌症预防、早期发现、治疗与幸存者照护，2025 年影响因子为 685.2。

Scope

• As the flagship journal of the American Cancer Society, CA publishes information about the prevention, early detection, and treatment of cancer, as well as nutrition, palliative care, survivorship and other topics related to cancer care作为美国癌症学会的旗舰期刊，CA 刊载癌症预防、早期发现与治疗的信息，以及营养、姑息治疗、幸存者照护与其他癌症照护主题。
• It provides cancer care professionals with up-to-date information on all aspects of cancer diagnosis, treatment and prevention该刊为癌症照护专业人员提供癌症诊断、治疗与预防各方面的最新信息。
• It publishes scientific and educational content in the form of comprehensive review articles on important cancer topics and issues该刊以针对重要癌症议题的综合性综述文章形式刊载科学与教育内容。
• It also publishes the latest American Cancer Society guidelines and statistical reports, including the widely cited annual Cancer Statistics report该刊亦刊载美国癌症学会最新的指南与统计报告，包括被广泛引用的年度《癌症统计》报告。^[1]
• It accepts proposals for high-impact phase III randomised trials that inform standards of care该刊接受能影响诊疗标准的高影响力 III 期随机试验的投稿提案。
• Its content reaches a diverse readership of oncologists, oncology nurses, primary care clinicians, general surgeons, gynaecologists and other professionals who interact with patients with cancer其内容面向肿瘤科医师、肿瘤科护士、基层临床医师、普外科医师、妇科医师等与癌症患者接触的各类专业人员这一多元读者群。
• It is an open access journal, so authors of accepted articles pay an article publication charge and their work is published under a Creative Commons licence该刊为开放获取期刊，被接收文章的作者需支付文章处理费，其成果以知识共享许可协议出版。

History

• It was founded in 1950 by the American Cancer Society as CA: A Bulletin of Cancer Progress, with volume 1, number 1 issued in November 1950该刊由美国癌症学会于 1950 年创办，初名 CA: A Bulletin of Cancer Progress，第一卷第一期于 1950 年 11 月出版。^[2]
• Its founding editor was Charles S. Cameron, who sought to condense authentic information about the diagnosis, treatment and control of cancer for general practitioners其创刊主编为 Charles S. Cameron，他致力于为全科医师浓缩关于癌症诊断、治疗与控制的可信信息。^[3]
• It was later renamed to CA: A Cancer Journal for Clinicians and has been published continuously since its founding, celebrating its 75th year in 2025该刊后来更名为《CA：临床医师癌症杂志》（CA: A Cancer Journal for Clinicians），自创刊以来持续出版，并于 2025 年迎来第 75 周年。
• It has long been published by Wiley on behalf of the American Cancer Society, and the National Library of Medicine records it as a bimonthly journal of the United States该刊长期由 Wiley 代表美国癌症学会出版，美国国家医学图书馆记其为美国的双月刊。
• Its dedicated online site, CA Online, was launched in September 2002 and was originally hosted by HighWire Press of Stanford University其专属在线站点 CA Online 于 2002 年 9 月上线，最初由斯坦福大学的 HighWire Press 托管。^[4]
• Its Journal Impact Factor has been highly volatile, reaching 503.1 in 2023, 232.4 in 2024 and 685.2 in 2025 according to Journal Citation Reports据期刊引证报告，其影响因子波动剧烈，2023 年为 503.1，2024 年为 232.4，2025 年为 685.2。
• It has been indexed in MEDLINE since 1965 and remains the journal with the highest impact factor of all journals ranked by Clarivate该刊自 1965 年起被 MEDLINE 收录，至今仍是 Clarivate 排名中影响因子最高的期刊。

Editors

• The editor-in-chief is Don S. Dizon, professor of medicine and surgery at Tufts University School of Medicine, a specialist in gynaecologic and pelvic malignancies现任主编为 Don S. Dizon，塔夫茨大学医学院医学与外科学教授，专长于妇科与盆腔恶性肿瘤。
• He followed an editorial leadership change announced in 2023, when Arif Kamal, chief patient officer of the American Cancer Society, became editor-in-chief其接任源于 2023 年宣布的编辑领导层更替，当时美国癌症学会首席患者官 Arif Kamal 出任主编。
• The previous editor was Ted Gansler, who served the journal for more than 23 years and is now listed as editor emeritus上一任编辑为 Ted Gansler，任职逾 23 年，现列为荣誉编辑。
• A large editorial advisory board of more than fifty members draws mainly on United States institutions, including Emory University, MD Anderson, Mayo Clinic and Memorial Sloan Kettering Cancer Center一个逾五十人的大型编辑顾问委员会主要来自美国机构，包括埃默里大学、MD 安德森癌症中心、梅奥诊所与纪念斯隆凯特琳癌症中心。
• The journal is guided by an American Cancer Society Advisory Council, whose chief scientific officer William L. Dahut oversees the Society's research strategy该刊由美国癌症学会顾问委员会指导，其首席科学官 William L. Dahut 主管学会的研究战略。
• Peer review is rigorous, with a median of two days to first decision, 28 days to acceptance and 39 days from acceptance to publication同行评审严格，投稿至首次决定的中位数为两天，至接收为 28 天，接收至出版为 39 天。
• It runs distinctive series such as virtual tumor boards, patient pages and American Cancer Society guideline collections该刊设有虚拟肿瘤委员会、患者专栏与美国癌症学会指南集等特色系列。